Latest Stock Buy or Sell? Make More Informed Decisions!

An analyst downgraded it today. The averaging selling prices for homes remain great, says the company, without signs of slowing. Q1 revenues were up 23% but slightly missed estimates. It's down nearly 10% in the past week. They fell short on the top and bottom lines. However, they have a very strong backlog to fulfill and management maintained their full-year forecast as the company expects higher prices. It now trades at a big discount to book value. Instead of buying back shares (at low share prices), the company would rather buy more homes. The homebuilders are cyclicals . Also, can they execute? Supply china shortages are a problem.

The CEO is doing a good job and we're about to go into the spring growing season. They also do gardening and renovation and not just home-building.

Home demand will remain strong will at least the end of the year, though skyrocketing labour and materials costs like lumber and metals are a a problem. Last week, KBH reported a disappointing quarter, though management raised parts of guidance. The averaging selling prices for homes (and demand) remain great, says the company, without signs of slowing. It trades at only 3.3x this year's earnings, so it could be a bargain. Q1 revenues were up 23% but slightly missed estimates. They reported great numbers in California. Shares are down nearly 10% in the past week after they fell short on the top and bottom lines last week. However, they have a very strong backlog to fulfill, and management maintained their full-year margin forecast as the company expects higher home prices. The CEO says their biggest challenge is completing homes. Shares now trade at a big discount to book value. If they start buying back stocks, he's in, but if not, he's on the sidelines.

Medical device-makers are safe in a weakening economy. Shares have soared over the past 12 years by 1,350%. The pandemic caused a big delay in surgeries, but it's now time for ABMD to shine. Their products (treating heart disease) are in high demand. Their most recent quarter was really good. True, this stock isn't cheap, but not neither are their peers.

He likes it for its growth and yield, but Wall Street doesn't.

Now, you need boring, low PE stocks, the opposite of those hurt by inflation, such as Alphabet or Meta. They sell at historically cheap PEs. In healthcare, Eli Lilly is his top pick.

Now, you need boring, low PE stocks, the opposite of those hurt by inflation, such as Alphabet or Meta. They sell at historically cheap PEs. In healthcare, Eli Lilly is his top pick.

Now, you need boring, low PE stocks, the opposite of those hurt by inflation, such as Alphabet or Meta. They sell at historically cheap PEs. In healthcare, Eli Lilly is his top pick.